Literature DB >> 14999620

Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.

Javier Aspa1, Olga Rajas, Felipe Rodríguez de Castro, José Blanquer, Rafael Zalacain, Asunción Fenoll, Rosa de Celis, Antonio Vargas, Francisco Rodríguez Salvanés, Pedro Pablo España, Jordi Rello, Antoni Torres.   

Abstract

A multicenter study of 638 cases of community-acquired pneumonia due to Streptococcus pneumoniae (SP-CAP) was performed to assess current levels of resistance. Of the pneumococcal strains, 35.7% had an minimum inhibitory concentration (MIC) of penicillin of > or =0.12 microg/mL (3 isolates had an MIC of 4 microg/mL), 23.8% had an MIC of erythromycin of 128 microg/mL, and 22.2% were multidrug resistant. Logistic regression determined that chronic pulmonary disease (odds ratio [OR], 1.44], human immunodeficiency virus infection (OR, 1.98), clinically suspected aspiration (OR, 2.12), and previous hospital admission (OR, 1.69) were related to decreased susceptibility to penicillin, and previous admission (OR, 1.89) and an MIC of penicillin of MIC > or =0.12 microg/mL (OR, 15.85) were related to erythromycin resistance (MIC, > or =1 microg/mL). The overall mortality rate was 14.4%. Disseminated intravascular coagulation, empyema, and bacteremia were significantly more frequent among patients with penicillin-susceptible SP-CAP. Among isolates with MICs of penicillin of > or =0.12 microg/mL, serotype 19 was predominant and was associated with a higher mortality rate. In summary, the rate of resistance to beta -lactams and macrolides among S. pneumoniae that cause CAP remains high, but such resistance does not result in increased morbidity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999620     DOI: 10.1086/381886

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.

Authors:  Seong-Ho Choi; Jin-Won Chung; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.

Authors:  Trudy H Grossman; Douglas J Bartels; Steve Mullin; Christian H Gross; Jonathan D Parsons; Yusheng Liao; Anne-Laure Grillot; Dean Stamos; Eric R Olson; Paul S Charifson; Nagraj Mani
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

4.  Antimicrobial resistance of Streptococcus pneumoniae isolates in Athens, Greece.

Authors:  S Kanavaki; E Mantadakis; S Karabela; M Anatoliotaki; M Makarona; H Moraitou; A Pefanis; G Samonis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

Review 5.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

6.  Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Authors:  Pierre Abgueguen; Esther Azoulay-Dupuis; Violaine Noel; Pierre Moine; Veronique Rieux; Bruno Fantin; Jean-Pierre Bedos
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

Review 7.  Is antibiotic resistance a problem? A practical guide for hospital clinicians.

Authors:  G Barlow; D Nathwani
Journal:  Postgrad Med J       Date:  2005-11       Impact factor: 2.401

8.  In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class.

Authors:  Nagraj Mani; Christian H Gross; Jonathan D Parsons; Brian Hanzelka; Ute Müh; Steve Mullin; Yusheng Liao; Anne-Laure Grillot; Dean Stamos; Paul S Charifson; Trudy H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

9.  Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae isolated from patients with community-acquired pneumonia and molecular analysis of multidrug-resistant serotype 19F and 23F strains in Japan.

Authors:  L Qin; H Watanabe; H Yoshimine; H Guio; K Watanabe; K Kawakami; A Iwagaki; H Nagai; H Goto; T Kuriyama; Y Fukuchi; T Matsushima; S Kudoh; K Shimada; K Matsumoto; T Nagatake; T Mizota; K Oishi
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

10.  Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.

Authors:  M Raquel Marín Jiménez; Juan Luis Muñoz Bellido; José Angel García Rodríguez
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.